ClinicalTrials.gg
CompletedNCT00833560Updated Nov 21, 2014Results posted

A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

A Phase 2 interventional study of Cyclophosphamide and Bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag G.m.b.H. Completed at 35 sites in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-11-21.

Sponsored by Janssen-Cilag G.m.b.H (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
401
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 171 studies testing cyclophosphamide in Multiple Myeloma — 15 open to participants now, 27 under way, 1 of them phase 3. Cyclophosphamide · Multiple Myeloma.

Enrollment
6th of 167
401 · median 41
Started
2006
with 9 others
Phase 2
92 of 171
8 open now
Registered
56th of 171
by date

Among the 171 studies testing cyclophosphamide in Multiple Myeloma, this one is the 6th largest by enrollment of the 167 interventional ones that give a count, is one of 10 that started in 2006, is one of 92 in phase 2, and was the 56th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 171 studies testing cyclophosphamide in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies testing cyclophosphamide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.

Read the detailed description

This is open-label (both the participant and the investigator know what treatment participants will receive), prospective (participants are identified and then followed forward in time for the outcome of the study), multi-centre, and non-randomized (participants are assigned to different treatment groups by the investigator) study. The study will be conducted into 2 parts (Part 1 and Part 2). Approximately 400 participants will be enrolled (30 in Part 1 and 370 in Part 2). In Part 1 the optimum dose of cyclophosphamide will be evaluated and in Part 2 the selected dose of cyclophosphamide from Part 1 will be administered. Part 2 will include a screening period of a maximum of 14 days followed by chemotherapy (bortezomib, cyclophosphamide, and dexamethasone) of a maximum of three 21-day cycles. Safety will be evaluated by the assessment of adverse events, vital signs, physical examination, electrocardiogram, and clinical laboratory tests which will be monitored throughout the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Untreated multiple myeloma
  • Bortezomib
  • VELCADE
  • Cyclophosphamide
  • Dexamethasone
  • Chemotherapy
  • Remission therapy
  • Induction therapy
  • Stem Cell Transplantation
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or histologically diagnosed with multiple myeloma stage II/III
  • Participants without preceding cytostatic (tending to retard cellular activity and multiplication) treatment (pretreatment with radiation or dexamethasone is allowed)
  • Agree to use one of the methods as defined in the protocol
  • performance status 60 percent or more
  • Adequate laboratory test values

Exclusion criteria

Exclusion Criteria:

  • Non-secretory multiple myeloma
  • Estimated less than 3 months
  • History of cancer (except basal cell carcinoma) in the last 5 years
  • Peripheral neuropathy (disorder of the peripheral nerves) grade 2 or more
  • Positive test and active and/or
  • Pregnant or breast-feeding female participants
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Cyclophosphamide + Bortezomib + Dexamethasone

    Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.

    Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.

  • Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).

    Also known as: VELCADE

  • Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).

06

What researchers measure

Primary outcomes

  1. Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set)

    CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.

    Time frame: Up to Day 63

Secondary outcomes

  1. Participants With Complete Response (CR) + Partial Response (PR) (Per-protocol Analysis Set)

    CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.

    Time frame: Up to Day 63

  2. Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Efficacy Set)

    Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible

    Time frame: Up to Day 63

  3. Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Per-protocol Set)

    Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible.

    Time frame: Up to Day 63

07

Results

Posted Mar 3, 2014

Participant flow

401 participants were enrolled at 41 study sites in Germany.

Participant flow — Overall Study
MilestoneCyclophosphamide + Bortezomib + Dexamethasone
Started395
Completed353
Not completed42
Withdrew: Toxicity13
Withdrew: Adverse event11
Withdrew: Protocol violation6
Withdrew: Lack of efficacy4
Withdrew: Death2
Withdrew: Pregression of other disease1
Withdrew: Other5

Outcome measures

PrimaryParticipants With Complete Response (CR) + Partial Response (PR) (Efficacy Set)

CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.

Time frame:
Up to Day 63
Reported as:
Number · Participants
Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set)
ParticipantsCyclophosphamide + Bortezomib + Dexamethasone
Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set)334
Statistical analysis
  • Cyclophosphamide + Bortezomib + Dexamethasone · Two - sided binomial test · p = <0.0001 · Percentage of participants with response: 85.4 · 95% CI 81.5 to 88.8
SecondaryParticipants With Complete Response (CR) + Partial Response (PR) (Per-protocol Analysis Set)

CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.

Time frame:
Up to Day 63
Reported as:
Number · Participants
Participants With Complete Response (CR) + Partial Response (PR) (Per-protocol Analysis Set)
ParticipantsCyclophosphamide + Bortezomib + Dexamethasone
Participants With Complete Response (CR) + Partial Response (PR) (Per-protocol Analysis Set)284
Statistical analysis
  • Cyclophosphamide + Bortezomib + Dexamethasone · Two-sided binomial test · p = <0.0001 · Percentage of participants with response: 87.7 · 95% CI 83.6 to 91.0
SecondaryPercentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Efficacy Set)

Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible

Time frame:
Up to Day 63
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Efficacy Set)
Percentage of participantsCyclophosphamide + Bortezomib + Dexamethasone
13q- (n=112)90.2
t (4;14) (n=38)89.5
17p- (n=31)74.2
Other (n=104)87.5
No changes (n=102)84.3
SecondaryPercentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Per-protocol Set)

Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible.

Time frame:
Up to Day 63
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Per-protocol Set)
Percentage of participantsCyclophosphamide + Bortezomib + Dexamethasone
13q- (n=92)92.4
t (4;14) (n=34)91.2
17p- (n=24)87.5
Other (n=87)88.5
No changes (n=87)85.1

Adverse events

Collected over From date of inform consent signed to 30 days after the last bortezomib dosing or, if earlier, until start of an alternative myeloma therapy.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclophosphamide + Bortezomib + Dexamethasone—103/395 (26.1%)392/395 (99.2%)
Most frequent serious events
Showing 10 of 98
Most frequent serious events
EventCyclophosphamide + Bortezomib + Dexamethasone
PneumoniaInfections and infestations15/395
PyrexiaGeneral disorders14/395
LeukopeniaBlood and lymphatic system disorders11/395
DiarrhoeaGastrointestinal disorders5/395
NeutropeniaBlood and lymphatic system disorders4/395
ConstipationGastrointestinal disorders4/395
NauseaGastrointestinal disorders4/395
PolyneuropathyNervous system disorders4/395
Cardiac failureCardiac disorders4/395
Herpes zosterInfections and infestations3/395
Most frequent other events
Showing 10 of 40
Most frequent other events
EventCyclophosphamide + Bortezomib + Dexamethasone
LeukopeniaBlood and lymphatic system disorders211/395
ThrombocytopeniaBlood and lymphatic system disorders129/395
NauseaGastrointestinal disorders105/395
ConstipationGastrointestinal disorders86/395
Oedema peripheralGeneral disorders79/395
AnaemiaBlood and lymphatic system disorders77/395
FatigueGeneral disorders76/395
DiarrhoeaGastrointestinal disorders73/395
ParaesthesiaNervous system disorders63/395
PyrexiaGeneral disorders56/395

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cyclophosphamide + Bortezomib + Dexamethasone
Mean52.4 ± 6.5
Age, Customized
Age, Customized(Participants)Cyclophosphamide + Bortezomib + Dexamethasone
Between 20 and 39 years17
Between 40 and 49 years109
Between 50 and 60 years253
>65 years16
Sex: Female, Male
Sex: Female, Male(Participants)Cyclophosphamide + Bortezomib + Dexamethasone
Female166
Male229
08

Study locations

35 sites
  • Berg, Germany
  • Berlin, Germany
  • Bremen, Germany
  • Dresden, Germany
  • Erlangen, Germany
  • Frankfurt / Main, Germany
  • Freiburg, Germany
  • Greifswald, Germany
  • Göttingen, Germany
  • Halle, Germany
  • Hamburg, Germany
  • Hamm, Germany
  • Hannover, Germany
  • Homburg, Germany
  • Jena, Germany
  • Karlsruhe, Germany
  • Kiel, Germany
  • Lübeck, Germany
  • Magdeburg, Germany
  • Mainz, Germany
  • Muenchen, Germany
  • Mutlangen, Germany
  • München, Germany
  • Münster, Germany
  • Nürnberg, Germany
  • Oldenburg, Germany
  • Potsdam, Germany
  • Regensburg, Germany
  • Rehling, Germany
  • Rostock, Germany
  • Stuttgart, Germany
  • Tübingen, Germany
  • Ulm, Germany
  • Villingen-Schwenningen, Germany
  • Würzburg, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2009
First posted
Feb 2, 2009
Start
Mar 2006
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Mar 3, 2014
Last update
Nov 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00833560
Responsible party
Sponsor
First posted
Feb 2, 2009
Start date
Mar 2006
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Mar 3, 2014
Last update
Nov 21, 2014

Study contacts

Janssen-Cilag G.m.b.H, Germany Clinical Trial
study director · Janssen-Cilag G.m.b.H

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Bortezomib · Dexamethasone

Start the discussion